Edition:
United Kingdom

Sellas Life Sciences Group Inc (SLS.OQ)

SLS.OQ on NASDAQ Stock Exchange Capital Market

5.70USD
23 May 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.70
Open
$5.70
Day's High
$5.76
Day's Low
$5.60
Volume
5,778
Avg. Vol
82,854
52-wk High
$19.32
52-wk Low
$3.43

Select another date:

Wed, May 23 2018

BRIEF-Sellas Life Sciences Files For Offering Of Up To $30 Mln

* SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO $30 MILLION - SEC FILING Source text: (https://bit.ly/2klt2uI) Further company coverage:

BRIEF-Sellas Life Sciences Receives FDA Orphan Drug Designation For Galinpepimut-S For Treatment Of Multiple Myeloma

* SELLAS LIFE SCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR GALINPEPIMUT-S (GPS) FOR TREATMENT OF MULTIPLE MYELOMA (MM) Source text for Eikon: Further company coverage:

BRIEF-Sellas Life Sciences Ceases Gregory Torre's Employment As Chief Regulatory Officer

* SELLAS LIFE SCIENCES GROUP- ON APRIL 19, CO AND GREGORY TORRE, AGREED THAT HIS EMPLOYMENT AS CHIEF REGULATORY OFFICER WOULD CEASE - SEC FILING

BRIEF-Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer

* SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER

BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin

* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS

BRIEF-Sellas Life Sciences Announces $10.7 Mln Private Placement

* SELLAS LIFE SCIENCES ANNOUNCES $10,700,000 PRIVATE PLACEMENT

Select another date: